3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Unknown
1
Sponsor Class
OTHER
17
INDUSTRY
10
NETWORK
4
NIH
2
OTHER_GOV
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Urinary Bladder Neoplasms
1
Recurrence
1
Interventions
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
3
Zoledronic Acid
3
Saline Solution
3
Gemcitabine
3
enzalutamide
2
darolutamide
2
Radiosurgery
2
Magnetic Resonance Spectroscopy
2
Magnetic Resonance Imaging
2
LHRH, Ac-Nal(1)-Cpa(2)-Trp(3)-Arg(6)-Ala(10)-
2
Androgen Antagonists
2
Abiraterone Acetate
2
veliparib
1
toripalimab
1
bemarituzumab
1
avelumab
1
apatorsen
1
apalutamide
1
anlotinib
1
aldesleukin
1
abiraterone
1
Watchful Waiting
1
Videotape Recording
1
Urination
1
Ultrasound, High-Intensity Focused, Transrectal
1
Transurethral Resection of Prostate
1
Tacrolimus
1
Surveys and Questionnaires
1
Surgical Procedures, Operative
1
Sunitinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER_GOV
×
BCG Vaccine
×
Genitourinary
×
Clear all
NCT03664869
2021-04-01
FB10
Turku University Hospital
Phase 3
Unknown
300 enrolled